Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Approves Record New Cancer, Orphan Drugs In 2020 But Access Challenges Remain

Rare Disease Therapies Nearly Double

Executive Summary

Throughout 2020, China’s drive to introduce more and newer drugs to the market did not slow but was rather accelerated by the COVID-19 pandemic. But can people afford them?

You may also be interested in...



Asia Deal Watch: CANbridge Licenses Orphan Disease Candidates From Mirum, LogicBio

US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.

Shanghai Pharma Manufacturing Halves In April

China's main pharma hub of Shanghai reported sector output has plunged by more than half due in large part to the prolonged lockdown, while 58% of surveyed foreign companies in China across all industries project declining revenue.

Homegrown China Oral Antiviral Shows Early Promise

Junshi’s oral antiviral shows signs of effectiveness in treating patients with mild COVID-19 symptoms but more data are needed, caution researchers.

Topics

Related Companies

UsernamePublicRestriction

Register

PS143647

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel